Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Part of paid clinical trials in Bethesda, Maryland.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00030537
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have locally advanced or metastatic breast cancer.

Key Dates

First listed
Jan 27, 2003
Start date
Nov 30, 2001
Status verified
Oct 2002
Completion
Mar 31, 2003

Study Design

Primary purpose
TREATMENT

Locations (2)

FacilityCityStateZIPSite coordinators
Center for Cancer ResearchBethesdaMaryland20889-5101-
Warren Grant Magnuson Clinical Center - NCI Clinical Studies SupportBethesdaMaryland20892-1182-

Find similar trials in Bethesda, MD

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Center for Cancer Research· Bethesda, MDWarren Grant Magnuson Clinical Center - NCI Clinical Studies Support· Bethesda, MD

Related Studies